scispace - formally typeset
G

Gouri Koduri

Researcher at University of Hertfordshire

Publications -  18
Citations -  1126

Gouri Koduri is an academic researcher from University of Hertfordshire. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 7 publications receiving 854 citations. Previous affiliations of Gouri Koduri include University of Cambridge.

Papers
More filters
Journal ArticleDOI

Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis

Adam Young, +6 more
- 14 Aug 2006 - 
TL;DR: There was a modest increase in mortality in RA, mainly in the first 7 yrs, but treatment-related deaths were low, and risk factors included less favourable socio-economic status, markers of disease severity and diminished function within the first year.
Journal ArticleDOI

Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort

Gouri Koduri, +10 more
- 01 Aug 2010 - 
TL;DR: RA-ILD is an important and early feature of RA, related to disease activity and has a poor prognosis, and further studies are required to determine whether screening for pulmonary disease would identify patients at an earlier stage.
Journal ArticleDOI

Extra-articular manifestations and complications of rheumatoid arthritis

Adam Young, +2 more
- 01 Oct 2007 - 
TL;DR: Early and more aggressive RA drug therapies are being employed and, although evidence from randomised studies is not available, this approach would seem appropriate in view of the adverse effect of extra-articular manifestations on RA outcomes.
Journal ArticleDOI

A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome

Sam Norton, +5 more
- 01 Jan 2013 - 
TL;DR: Significant comorbidity was present at the outset of RA, increasing with follow-up, mainly in cardiovascular, non-cardiac vascular and respiratory systems, and needed earlier detection and management in order to reduce its impact on outcome.
Journal ArticleDOI

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, +7885 more
- 03 Mar 2022 - 
TL;DR: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials.